Good morning. Elizabeth Cooney here, channeling the vacationing Ed Silverman’s Wednesday wisdom: We’ve made it this far (I think he means through the week), so why not carry on? Some news to start us off:

The U.S. will pay $1.95 billion for Pfizer (PFE) and BioNTech (BNTX) to produce and deliver 100 million doses of their jointly developed Covid-19 vaccine candidate in the U.S. if it proves safe and effective in humans, CNBC informs us. Under the agreement, the U.S. can acquire an additional 500 million doses, the Department of Health and Human Services said.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy